Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.
Background
Obesity is a public health epidemic currently affecting 37.7% of adults and 17% of children and adolescents in the United States. 1, 2 Globally, the number of obese individuals continues to rise. 3 This is particularly problematic because of the comorbidities associated with obesity, which include type 2 diabetes mellitus, hypertension, cardiovascular disease, stroke, gallbladder disease, metabolic syndrome, and several types of cancer. Furthermore, depression is more common in obese individuals than in the general population, and obesity is associated with higher all-cause mortality, morbidity, and lower quality of life. [4] [5] [6] [7] [8] [9] [10] The growing prevalence of this health problem has put a significant burden on our healthcare system. Recent estimates have reported that $147-210 billion is spent annually to treat obesity and its attributed comorbidities in the United States alone, therefore comprising about 21% of our healthcare spending. 11, 12 Weight loss has long been shown to decrease the comorbidities associated with obesity. 13 However, significant long-term weight loss is not often sustained through diet and exercise alone.
14 Therefore, the rapid increase in the prevalence of obesity has resulted in an increasing demand for treatment options that extend beyond the clinical guidelines of diet and exercise.
Bariatric surgery has been shown to be the most effective treatment, with the most significant weight loss and decrease in comorbidities, such as type 2 diabetes mellititus. 15, 16 A number of bariatric surgeries are currently offered, many of which function by altering gastric and intestinal anatomy to reduce the capacity for food and the absorption of nutrients. Some of these surgeries, including Rouxen-Y gastric bypass (RYGB), have also been found to induce physiological changes that support weight loss, such as reduction in levels of the hungerstimulating hormone ghrelin and increases in peptide YY (PYY) and glucagon-like peptide 1 (GLP-1), both of which induce satiety. Despite the clinical success, less than 2% of those who qualify for bariatric surgery will undergo an operation, primarily because of issues concerning associated risks, morbidity, cost, accessibility, and patient preference. 18 Furthermore, a significant fraction of obese individuals do not qualify for surgery. The least invasive medical treatment for obesity is pharmaceutical treatment. However, pharmaceutical approaches are far less efficacious than surgery, with 30% of patients prescribed the highest dose failing to achieve clinically significant weight loss. 19 Therefore, bariatric endoscopy may bridge a critical gap in the treatment of obesity.
Because endoscopic technology is much less invasive than surgery, advancements in the field of bariatric endoscopy allow physicians to treat a greater portion of those struggling with obesity. Specifically, endoscopic procedures are able to reach patients earlier in the onset of obesity, including pediatric patients and those with body mass indices (BMIs) between 30 and 35 kg/m 2 . In addition to increased applicability, endoscopic techniques have lower cost and lower risk than surgery and maintain the structural integrity of the stomach. Furthermore, because endoscopic procedures can be repeated throughout one's life, they are well suited to manage the chronic nature of obesity.
The field of bariatric endoscopy is much younger than the field of bariatric surgery; however, there are currently five bariatric endoscopic procedures approved by the U.S. Food and Drug Administration (FDA) for clinical use in the United States, and a number of others in various stages of development, testing, and use in other countries. Here, we describe the current state of bariatric endoscopic procedures and examine their effects not only on weight loss but also on metabolic profile.
Space-occupying devices
Space-occupying devices are traditionally inserted endoscopically to reduce available gastric volume; however, recent research indicates that intragastric balloons (IGBs), the most commonly utilized space-occupying devices, also function to delay gastric emptying. 20 Three IGBs were recently approved for 6-month clinical use in the United States, and additional balloons are undergoing clinical trials. The primary limitation of treatment with a space-occupying device is that obesity is a chronic problem, and these devices can only remain in situ temporarily. However, it is important to consider that these procedures can be repeated throughout one's life as needed, and for many patients are a more attractive option than surgery. Of note, the safety and effectiveness of successive use has not been specifically examined by the FDA; however, it has been used in clinical practice. 21 
Intragastric balloons
Orbera. The most commonly used IGB, which was approved for clinical use in the United States in 2015, is the Orbera IGB (Apollo Endosurgery, Austin, TX), previously known as the BioEnterics Intragastric Balloon (Allergan, Irvine, CA) ( Fig. 1) . 22 As it had been used commercially since 1991 outside of the United States, there is a large body of evidence supporting the use of the Orbera IGB.
Importantly, therapy with the Orbera IGB has been reported to result in significantly reduced metabolic disease, diabetes mellitus, hyperuricemia, hypertriglyceridemia, and hypercholesterolemiaall of which remained reduced at 1-year follow-up in an Italian study. 23 More recently, in a multicenter European study, Genco et al. found the rates of comorbidities at 3 years after Orbera therapy to also be significantly reduced. Specifically, in those who had diabetes at baseline (n = 78), 31% experienced complete resolution at 3-year follow-up. Moreover, complete resolution occurred in 44% of those with hypertension (n = 150), 34% of those with hypercholesterolemia (n = 168), 45% of those with dyslipidemia (n = 102), 47% of those with osteoarthropathy (n = 132), and 100% of those with respiratory disorders (n = 6). 24 Furthermore, an Italian center linked treatment with the Orbera IGB to positive outcomes in obese women who were previously infertile. 25 These lasting improvements in comorbidities and indications of metabolic syndrome are particularly noteworthy because the primary concern regarding treatment with IGBs is the tendency for partial weight regain after balloon removal.
A current systematic review of 26 studies (n = 6101) found the percent excess bodyweight loss (%EWL) at the time of removal (6 months) to be 36.2 ± 6.3%. 26 Most recently, results of a U.S. multicenter randomized clinical trial (n = 255) through 12 months have shown mean total bodyweight loss (%TBWL) in the Orbera group (n = 125) at 6, 9, and 12 months postinsertion to be 10.2%, 9.1%, and 7.6%, respectively, compared with 3.3%, 3.4%, and 3.1% in the lifestyle counseling group (n = 130). Notably, this multicenter trial was limited to patients with class 1 and 2 obesity (BMI 30-40 kg/m 2 ). 27 A recent meta-regression analysis demonstrated that there is no significant difference in the %TBWL following treatment with the Orbera IGB over a wide range of BMIs, thus indicating that this treatment option is suitable for patients with varying degrees of obesity. 28 However, the FDA has only approved Orbera for use in adults with a BMI between 30 and 40 kg/m 2 . It has been noted that the bulk of weight loss occurs in the first 3 months of therapy. 29 This is consistent with the results of a recent meta-analysis (n = 1683), which reported a %EWL at 12 months after balloon insertion (6 months postremoval) of 25.44% and a pooled %TBWL at 3, 6, and 12 months postimplantation of 12.3%, 13.16%, and 11.27%, respectively. 28 To examine the durability of the weight loss, Dastis et al. assessed outcomes at 2.5 years after balloon insertion. Successful weight loss was defined as ࣙ10% TBWL, both at 6 and 30 months follow-up. Of the 100 patients who underwent IGB therapy, 63 achieved successful weight loss at 6 months-at which point the balloon was removed-and 24 maintained this weight loss at 2.5 years follow-up. Notably, there was no structured weight maintenance program offered to patients in this study, which took place in Switzerland. 30 To combat weight regain, IGBs are often used repeatedly throughout a patient's life. Peker et al. compared back-to-back IGB treatment to that of laparoscopic adjustable gastric band surgery (LAGB) in a Turkish cohort and found that the weight loss at 12 months was more significant in those treated with the IGBs (n = 16) than in those treated with LAGB (n = 16). 31 However, Dumonceau et al., who studied patients in Geneva, Switzerland, and Brussels, Belgium, reported that, at 5 years follow-up, patients who had undergone either single (n = 119) or repeated (n = 19) IGB placement were equally likely to have achieved ࣙ10% TBWL. 21 Rates of adverse events were assessed in a manual review of 68 studies. Early removal of the IGB occurred in 7% of patients. The most common adverse events, occurring in 33.7% of patients, were pain and nausea. Serious adverse events were rare and included migration in 1.4% of patients and gastric perforation in 0.1%. Of the eight documented gastric perforations that occurred, four occurred in patients who had previously undergone gastric surgery. Four Orbera-associated deaths have been reported owing to gastric perforation or an aspiration event. 32 Recently, the FDA issued a notice regarding the risk of acute pancreatitis and overinflation in fluid-filled balloons.
Mechanistically, the Orbera IGB is a single, spherical balloon composed of silicone. During insertion, the IGB is preloaded onto a catheter, deployed into the gastric fundus, and then inflated with 450-700 mL saline solution. In clinical practice, methylene blue is often mixed with the saline to serve as a potential in-urine indicator were the balloon to rupture; however, the safety and effectiveness of this practice have not been examined by the FDA. The procedure is performed under light sedation on an outpatient basis, and patients should be able to return to work in a few days, although transitioning to solid foods may take up to 2 weeks. After 6 months, the balloon must be removed endoscopically. Balloon removal is generally performed under general anesthesia and requires first puncturing the balloon with a needle and emptying the saline with a catheter and then using grasping forceps or a polypectomy snare to remove the deflated balloon.
As with the other FDA-approved balloons, the Orbera IGB will likely be more commonly used in the United States over the course of the next few years.
ReShape. The ReShape IGB, which was approved by the FDA in July 2015, is a dual-balloon device designed for increased satiety and resistance against migration. Changes in metabolic profile and comorbidities as a result of this therapy have yet to be examined directly; however, significant weight loss has been documented.
In a pivotal U.S. multicenter clinical trial (n = 326), patients were randomized to ReShape IGB treatment in addition to lifestyle counseling (n = 187) or sham endoscopy and lifestyle counseling (n = 139) for 6 months. Weight loss with the ReShape IGB was more than twice that of the control group, with 27.9% EWL in completers (n = 167) compared with 12.3% EWL in control group completers (n = 126).
The adverse event profile was low. Balloon deflation occurred in 6% of patients; however, no migrations occurred as a result of deflation. Initially, gastric ulcers occurred in 39.6% of patients; however, the device was then modified, and consequentially the rate of ulceration decreased to 10.3%, and the size of subsequent ulcers decreased significantly. Only one ulcer was clinically significant, as it resulted in a hemorrhage that required blood transfusion. Three serious adverse events occurred during retrieval: one esophageal mucosal tear that required hemoclip treatment, one cervical esophagus perforation that was managed conservatively with antibiotics, and one postretrieval aspiration pneumonitis. 33 A smaller, single-arm Spanish study (n = 60) had similar outcomes. 34 As previously mentioned, the FDA recently issued a notice regarding the risk of acute pancreatitis and overinflation in fluid-filled balloons.
The ReShape IGB is distinct from other IGBs, as it is composed of two silicone balloons connected by a flexible tether (Fig. 2) . The device is inserted endoscopically and then inflated with up to 450 mL saline methylene blue in each balloon, up to 900 mL total. Notably, each of the two balloons has independent channels so that unintended deflation in one balloon will not deflate the other balloon, but rather the inflated balloon will keep the deflated balloon from migrating. Like the Orbera IGB, this IGB is indicated for 6 months of treatment, but can be repeated. Of note, the FDA has only approved the ReShape IGB for treatment of adults with a BMI between 30 and 40 kg/m 2 .
Obalon. Most recently approved by the FDA in September 2016, the Obalon IGB (Obalon Thera- peutics Inc., Carlsbad, CA) is unique in that it is inserted via ingestion rather than endoscopy. The multicenter U.S. pivotal trial (n = 387) compared the outcomes of patients who underwent treatment with the Obalon IGB and lifestyle counseling (n = 185) to a control group of sham capsules and lifestyle counseling (n = 181). At 24 weeks, significant improvements in systolic blood pressure, fasting glucose, low-density lipoprotein (LDL) cholesterol, and triglycerides were noted in the treatment group but not in the control group. The %TBWL was 6.81 ± 5.1% in the treatment group and 3.59 ± 5.0% in the control group. One serious adverse event occurred, which was a gastric ulcer that was managed conservatively. Nonserious adverse events occurred in 89.9% of subjects-99.7% of which were rated mild or moderate. The most common of these events were nausea and abdominal cramping. 35 The Obalon IGB has also been studied for use specifically in the treatment of pediatric obesity in Italy, with positive outcomes. Specifically, at 3 months postinsertion, Nobili et al. reported significant improvement in alanine aminotransferase (51.44 ± 19.04 to 27.00 ± 13.38, P = 0.01), total and LDL cholesterol (179.8 ± 14.91 to 144.78 ± 14.36, P = 0.001 and 99.62 ± 24.09 to 93.11 ± 17.14, P = 0.001), insulin (27.40 ± 5.68 to 18.13 ± 7.67, P = 0.01), HOMA-IR (5.85 ± 1.53 to 3.84 ± 2.09, P = 0.03), and uric acid (7.32 ± 0.28 to 5.08 ± 1.23, P = 0.001). 36, 37 In order for this IGB to be inserted via ingestion rather than endoscopy, it is packaged inside of a gelatin capsule with an attached valve and catheter and is inflated with gas rather than saline solution. The catheter extends through the mouth to the stomach, allowing for inflation. The gelatin subsequently dissolves within the stomach, and the balloon is inflated using fluoroscopic imaging. Up to three balloons can be inserted in this fashion, either at the same time or progressively throughout treatment. The IGB can remain in situ for up to 24 weeks (ß6 months), and device retrieval must be performed endoscopically. As with other FDAapproved IGBs, the Obalon device has only been approved by the FDA for use in adults with a BMI between 30 and 40 kg/m 2 .
Spatz. The Spatz adjustable balloon system (Spatz Medical, Great Neck, NY) is unique in that it allows for in situ volume adjustment, which can be used to increase patient tolerance (deflation) or enhance efficacy (inflation), and it has been approved for 12-month therapy outside of the United States. Currently, a pivotal U.S. multicenter clinical trial is underway; the results of small observational trials have indicated significant weight loss despite a potentially concerning adverse event profile. A small pilot study (n = 18) conducted in the Czech Republic found %EWL at 6 and 12 months to be 26.4% and 38.8%, respectively. This study showed the adjustment feature to be useful for tolerability and weight loss following plateaus; however, 39% of the IGBs were removed prematurely because of various adverse events, including gastritis (1), deflation (1), Mallory-Weiss tear (1), perforating ulcer (1), and catheter shear (2). 38 Similarly, Brooks et al. reported results in 73 patients in the United Kingdom. In those with successful insertion (n = 70), the rate of early removal was 30%, owing to reported premature satisfaction (14) , intolerance refusing adjustment (4), and deflation (3)-although notably without migration. At 12 months (in 49 patients and <12 months in 21 patients owing to premature removal), the %EWL was 45.7%. Two asymptomatic ulcers were discovered upon retrieval, and three catheter impactions required surgical extraction. 39 When compared specifically to the Orbera IGB in an Italian cohort, the Spatz IGB showed comparable weight loss with a higher rate of complications. 40 The Spatz IGB is similar to the Orbera IGB in that it is a single IGB that is placed endoscopically and filled with 400-800 mL saline solution. However, a potential source of the increased rate of adverse events with this IGB may be the attached catheter, which is a unique component of this IGB designed to prevent migration.
Because this IGB has been approved for 12-month treatment outside of the United States, it may serve as a more durable treatment option if the adverse event profile can be improved. Upon the conclusion of the U.S. pivotal trial that is currently underway, the potential of this device will be better understood.
Elipse. The Elipse balloon (Allurion Technologies, Wellesley, MA) is unique in that it is completely "endoscopy-less," meaning that it is designed for passive excretion from the gastrointestinal tract, in addition to placement via ingestion.
In a small pilot study (n = 8) conducted in the Czech Republic, patients swallowed one Elipse capsule intended to remain in situ for 6 weeks. The balloon remained full through 6 weeks, self-emptied, and passed as intended in six of eight patients. At 6 weeks, the mean %EWL was 12.4%. One patient had the balloon endoscopically punctured owing to partial collapse, and one patient elected to have the balloon endoscopically removed; however, no serious adverse events occurred. of these initial trials are promising, and plans for a U.S. multicenter clinical trial may be on the horizon.
Nonballoon space-occupying devices
Transpyloric Shuttle. The Transpyloric Shuttle (TPS, BAROnova Inc., Goleta, CA) was examined in a small Australian trial (n = 20). Marinos et al. reported promising results, with %EWL of 25.1 ± 14.0% at 3 months and 41.0 ± 21.1% at 6 months postinsertion. The most common adverse event was gastric ulceration, which resulted in premature removal of the device in 10% of patients. 43 The device is composed of two silicone bulbs connected via a flexible catheter. The larger of the two bulbs is spherical and is designed to prevent migration, while the smaller of the two is cylindrical with the purpose of advancing into the duodenum via peristalsis. This mechanism produces an intermittent obstruction because of the larger bulb against the pylorus, which hypothetically will cause a delay in gastric emptying, thereby inducing early and prolonged satiety. The device is inserted via endoscopy and functions without an anchor.
A pivotal multicenter, randomized clinical trial designed to test the safety and effectiveness of this device has recently completed its cohort enrollment. The results of this study will likely elucidate this device's potential for widespread clinical use and potential metabolic improvement.
Gastric restrictive methods
Gastric restrictive methods function to restrict stomach volume, and some mechanisms also use techniques hypothesized to delay gastric emptying. Transoral gastroplasty is the predominant subcategory within gastric restrictive procedures. This mechanism involves the use of suturing, stapling, or tissue anchor placement to alter the morphology of the stomach.
Transoral gastroplasty
Endoscopic sleeve gastroplasty. Endoscopic sleeve gastroplasty (ESG) is a transoral gastroplasty procedure that utilizes an FDA-approved fullthickness endoscopic suturing system (OverStitch; Apollo Endosurgery, Austin, TX) to reduce gastric volume by approximately 70%. Of note, ESG is not an FDA-approved procedure, and the OverStitch device has not been specifically approved for the treatment of obesity. Rather, the OverStitch device has been approved for a general tool claim of endoscopic placement of sutures.
Sharaiha et al. recently reported weight loss and metabolic outcomes at 6, 12, and 24 months post-ESG in a U.S. cohort. At 12-month post-ESG, metabolic profiles were assessed and compared to baseline levels, which showed a significant reduction in markers of diabetes, hypertension, and hypertriglyceridemia. HbA1c levels were decreased in the entire cohort, from 6.1% ± 1.1% at baseline to 5.5% ± 0.48% at 12 months postprocedure (P = 0.05). In those with diabetes or prediabetes at baseline, HbA1c levels were reduced from 6.6% ± 1.2% to 5.6% ± 0.51% (P = 0.02). Furthermore, of the 13 patients taking medication for diabetes at baseline, five patients had stopped insulin and two had stopped all medications at 12-month follow-up. Significant reduction was also seen in systolic blood pressure, from 129.0 ± 13.4 mmHg at baseline to 122.2 ± 11.69 mmHg at 12 months (P = 0.02), as well as in serum triglycerides, from 131.84 ± 83.19 mmol/dL to 92.36 ± 39.43 mmol/dL (P = 0.02), and alanine aminotransferase, from 42.4 to 22 in men (P = 0.05), and 28 to 20 in women (P = 0.01). 44 At 6 months, patients had a mean of 14.4% TBWL (80% follow-up rate); at 12 months, the %TBWL was 17.6% (76% follow-up rate); and at 24 months, the %TBWL further increased to 20.9% (66% follow-up rate). 44 The most recent trials conducted at individual centers in the United States and Spain have reported %EWL over 50% at 6 months and 1 year postprocedure. [45] [46] [47] A multicenter study (n = 242) spanning the United States and Spain reported weight loss through 18 months in 30 subjects who were available for follow-up at that time. The %TBWL at 18 months was 19.8 ± 11.6%. 48 This study was therefore expanded to a 24-month follow-up, with 92 patients returning to participate. In this cohort, the TBWL was 18.6% (95% CI 15.7-21.5), without differing significantly between the three centers (P = 0.7). Further, 84% and 56% of the cohort achieved ࣙ10% and ࣙ15% TBWL at 24 months on per protocol analysis. 49 ESG appears to decrease caloric intake through increased satiation. However, Abu Dayyeh et al. recently studied the induction of physiological changes that promote weight loss post-ESG in a U.S. cohort. These changes parallel those seen after bariatric metabolic surgery and include a decrease in the appetite-stimulating hormone ghrelin, an increase in insulin sensitivity, and a delay in gastric emptying. 45 The rate of adverse events post-ESG is minimal, with a number of series reporting zero events. 46, 50 In the larger multicenter study, adverse events occurred in 2% of patients, comprising two cases of perigastric inflammatory fluid collection, one case of hemorrhage, one case of pulmonary embolism, and one case of pneumoperitoneum and pneumothorax that required chest tube placement. All five patients recovered fully, with no further need for surgery. 48, 49 One clinical trial reported an incidence of a perigastric leak, which was managed nonoperatively. 44 The gastric remodeling that occurs in this procedure mimics that of laparoscopic sleeve gastrectomy surgery; however, no incisions are made. In this procedure, sutures are placed in two rows along the greater curvature of the stomach, in a triangular pattern from the anterior wall to the greater curvature to the posterior wall. The result is a gastric cavity that forms a tubular sleeve along the lesser curvature, with the greater curvature closed off by plications from the gastroesophageal junction to the prepyloric antrum (Fig. 3) . 47, 51, 52 ESG is an outpatient procedure, and patients generally return to full functionality within 1-3 days post-ESG. 45 However, patients are instructed to follow a liquid diet for 3 days postprocedure before transitioning to smooth, pureed foods and then to soft and then solid foods in 2-week intervals.
ESG is unique among endoscopic techniques in that, although it can be reversed, it can also serve as a durable alteration to gastric volume. Further, if plications were found to break down over time, ESG can be repeated as needed, as was recently reported with positive outcomes. 46, 47, 53 Primary obesity surgery endoluminal. Primary obesity surgery endoluminal (POSE) is another transoral gastroplasty procedure; however, POSE depends on an Incisionless Operating Platform (IOP) (USGI Medical, San Clemente, CA) to place full-thickness tissue-anchor plications and is currently being examined by the FDA for safety and efficacy.
To date, the results of four studies assessing the safety and efficacy of POSE have been published, and one study has examined the physiological effects of the procedure. Lopez-Nava et al. assessed the outcome of POSE treatment in a prospective singlearm trial (n = 147) in Spain and found that, in the 116 patients available for follow-up at 1 year, the mean %EWL was 44.9 ± 24.4 (15.1 ± 7.8 %TWL). Further, patients tolerated the procedure well, with no serious short-term or long-term adverse events. 54 Similarly, Espinos et al. assessed these outcomes at 6 months (n = 45) in a Spanish cohort and found %EWL of 49.4% (15.5% TBWL). Adverse events that required additional hospitalization included one case of low-grade fever and one case of chest pain. Common side effects included nausea, gastric pain, and chest pain. Notably, Espinos et al. included patients with type 3 obesity, whereas other studies of POSE were limited to type 1 and 2 obesity. 55 Miller et al. assessed the outcomes of POSE treatment in a controlled, multicenter European clinical trial comparing 12-month weight loss results in patients who underwent POSE in addition to lifestyle counseling (n = 30) to those who had lifestyle counseling alone (n = 9). They reported a mean of 45.0% EWL (13.0% TBWL) in the POSE group compared with 18.1% EWL (5.3% TBWL) in the control group. The mean procedure time in this study was 51.8 ± 14.5 minutes. 56 A pivotal multicenter U.S. clinical trial assessed these outcomes in a similar fashion in a larger sample, comparing treatment with POSE in addition to lifestyle intervention (n = 221) to lifestyle intervention alone (n = 111). In this trial, the %TBWL at 12 months in the POSE group was 4.94 ± 7% compared with 1.38 ± 5.6% in the control group. The rate of serious adverse events in this trial was 4.7%, which consisted primarily of postprocedural nausea, vomiting, and/or pain requiring a prolonged hospital stay. Notably, the mean procedure time in this study was 39.7 ± 12.9 minutes. 57 Recently, Espinos et al. conducted the first study assessing the physiological changes that occur as a result of the POSE procedure (n = 18). At 2 and 6 months postprocedure, intake capacity was decreased significantly from baseline levels (P < 0.001). Gastric emptying was also delayed at 2 months but returned to baseline levels at 6 months postprocedure. Further, patients experienced improved glucose homeostasis as well as satiation peptide responses. Specifically, the glucose/insulin ratio improved (P < 0.05), and postprandial decrease in ghrelin was enhanced (P = 0.03), as was postprandial increase in PYY (P = 0.001). The procedure resulted in significant sustained weight loss at 15 months, with %EWL of 63.7 ± 25.1% (19.1 ± 6.6% TWL), which may be mediated through these changes in gastrointestinal neuroendocrine physiology. 58 The specific mechanism reduces the accommodation of the gastric fundus via 8-10 plications placed in a dual-ridge fashion to bring the fundic apex to the level of the gastroesophageal junction, thus inhibiting full gastric expansion. Three to four additional plications are placed in a single ridge in the distal gastric body (across from the insura) to delay gastric emptying.
The IOP has four channels, accommodating a slim endoscope and three procedure-specific instruments: the g-Prox EZ Endoscopic Grasper (USGI Medical, San Clemente, CA), a shaft capable of 360°rotation equipped with stainless steel jaws to create full thickness tissue folds; the g-Lix Tissue Grasper (USGI Medical), a helical probe that gasps tissue and feeds it to the g-Prox; and the g-Cath EZ Suture Anchor Delivery Catheter (USGI Medical), a catheter system that penetrates the target tissue and deploys suture anchors. Generally, the procedure and associated recovery time requires that patients spend <24 h in the hospital. Following the procedure, patients advance from a clear liquid diet to a soft pureed diet during the first month and then to solid food by 6 weeks.
If approved by the FDA, this procedure will likely garner more widespread use.
Transoral gastroplasty device. The transoral gastroplasty device (TOGA, Satiety Inc., Palo Alto, CA) is an endoscopic stapler capable of full-thickness tissue apposition that has been used in transoral gastroplasty in a number of trials.
Deviere et al. first conducted a multicenter study on this technique in 2008 (n = 21) and found 24.4% EWL at 6 months. All patients had persistent full or partial stapled sleeves, although 62% of patients had a gap in the staple line. 59 Since then, the technique has been improved by the addition of an adjustable septum, allowing closer apposition of the staple lines. In a pilot study conducted in Belgium using the second-generation device (n = 11), Moreno et al. reported 46 .0% EWL at 6 months and no serious adverse events. 60 Familiari et al. conducted a multicenter European single-arm clinical trial (n = 67) and reported improvements in metabolic profile at 12 months. Specifically, HbA1c levels decreased (P = 0.1), triglyceride levels decreased (P < 0.0001), and highdensity lipoprotein levels increased (P < 0.0001). The %EWL was 38.1 ± 17.1% in the subjects who were available at follow-up (79%). Two complications occurred: a case of respiratory insufficiency and an asymptomatic pneumoperitoneum, both treated conservatively. The most common adverse effects were nausea, vomiting, and pain. 61 Recently, Nanni et al. compared the outcomes of this procedure (n = 29) with laparoscopic gastric bypass (LRYGB) (n = 20) and biliopancreatic diversion (BPD) (n = 30) in morbidly obese patients in Italy at 2 years postprocedure. This study concluded that, although the weight loss resulting from transoral gastroplasty with TOGA is less than that of LRYGB and BPD (32.45 ± 22.35% EWL at 2 years follow-up), the lack of adverse events in combination with the adequate weight loss both immediately postoperatively and sustained through 2-year follow-up demonstrated that TOGA is an effective alternative option for those who resist surgical intervention. 62 Using this device in transoral gastroplasty allows endoscopists to create a restrictive pouch along the lesser curvature of the stomach. The procedure takes approximately 1-2 h and is performed under general anesthesia. The TOGA stapler is introduced over a guide wire to the proximal stomach, and a gastroscope is advanced through for visualization. Tissue is gathered in the stapler via suction, and the stapler is fired, inserting three rows of 11 titanium staples. If necessary, this can be repeated to narrow the lumen further; however, the stapler must be removed for reloading. This mechanism was developed to induce satiety by limiting the capability for gastric expansion and by slowing the movement of food through stomach.
Regrettably, the manufacturer of the TOGA device, Satiety Inc., has closed, leaving the future of this technique uncertain.
Articulating circular endoscopic device. The articulating circular endoscopic device (ACE, Boston Scientific Corporation, Natick, MA) is another endoscopic stapling device that has recently begun being clinically studied for use in gastric volume reduction.
Results of the first human application of the technique, a prospective phase I clinical study (n = 17) conducted in the Netherlands, demonstrated that the procedure is technically feasible and safe and resulted in both weight loss and reduction in comorbidities. At 12 months, resolution of dyslipidemia had occurred in three of four patients and improved in one. Of the four patients with hypertension, two were in remission. Of the four patients with sleep apnea, two were in remission, and all patients with type 2 diabetes had either ceased (1) or reduced (1) insulin use. The median %EWL was 34.9% (IQR 17.8-46.6), and endoscopy revealed 6-9 intact plications, as well as durability of gastric volume reduction, in all participants available for follow-up (65%). Adverse events included gastric pain (n = 7, range 1-3 days), sore throat (n = 4, 2-3 days), diarrhea (n = 4, 2-15 days), nausea (n = 3, 2-4 days), constipation (n = 4, 3-14 days), and vomiting (n = 3, 1-4 days). No serious adverse events occurred, and the median procedure time was 123 min (IQR 95-129). 63 Since this first trial, Biertho et al. studied the outcomes of the procedure in 69 patients in a multicenter study. In the 45 patients available for follow-up at 2 years, the mean %EWL was 21.0 ± 30.4%. Furthermore, eating habits as assessed through the Threefactor Eating Questionnaire R18 were significantly improved at both 1 and 2 years postprocedure. 64 Mechanistically, this device is capable of 360°r otation, which allows the endoscopist to place staples where necessary. With this technique, tissue is suctioned into the stapler, and, upon firing, eight titanium staples are inserted, forming a fullthickness, transmural plication. The device is then removed, reloaded, and the procedure is repeated, creating up to eight plications in the fundus and two in the antrum of the stomach. These final two plications are hypothesized to delay gastric emptying in addition to further decreasing gastric volume.
The results of the initial trials are encouraging, and the potential of this device will likely be examined in further clinical trials.
Endomina device. The Endomina (EndoTool SA (STT), Gosselies, Belgium) is a triangulation platform being examined for use in transoral gastroplasty. Huberty et al. first studied this technique in 11 subjects in Belgium. At 6 months, the mean %EWL was 41 ± 33% in the patients who were available for follow-up (91%). No severe adverse events were noted, and the researchers concluded that device appears to be safe and effective in the short and middle term. The median length of procedure was 2 h (range 1.15-3.15 h); however, there is reason to believe that there is a learning curve for the operation. 65 This device functions by creating anterior-toposterior plications along the greater curvature of the stomach with the purpose of reducing gastric volume. The Endomina is an over-the-scope device that adds a bendable and nonbendable channel to an endoscope. It is used in conjunction with a Transmural Antero-Posterior Endoscopic Stitcher (TAPES) to deliver an interrupted suture that is anchored by two T-tags. This technique involves tightening pairs of plications to one another and is repeated four to six times per procedure.
The results of this small study are promising; however, larger studies will need to be performed before this technique can be fully understood.
Other gastric restrictive mechanisms
Transoral endoscopic restrictive implant system. The transoral endoscopic restrictive implant system (TERIS, BaroSense Inc., Redwood City, CA) is novel in that the procedure involves insertion of a restrictor at the gastric cardia that is designed to remain in situ permanently (however, it can be removed if necessary). This mechanism creates a restrictive pouch and a 10-mm channel for food to pass through. Interestingly, this procedure is under clinical investigation for the treatment of both obesity and gastroesophageal reflux disease (GERD). 66 De Jong et al. first studied this procedure in humans (n = 13) in the Netherlands and reported a mean of 28% EWL at 3 months postprocedure. Severe adverse events developed in 23% of patients, including one case of gastric perforation requiring laproscopic treatment and two cases of pneumoperitoneum. 67 More recently, Legner et al. studied the safety and effectiveness of this technique in a U.S.-led multicenter pilot study (n = 7) for the treatment of both GERD (three patients) and obesity (four patients). The procedure was not completed in the first two GERD patients owing to instrument malfunction. In the four patients treated for obesity, the mean %EWL was 30.3% at 2 years postprocedure. One patient vomited multiple times postoperatively, loosening the gastroplasty sutures, and another had an 8-mm outlet at the end of the procedure, which was corrected. 66 The safety of this procedure remains a concern; however, because of the permanent nature of the device, if technical improvements and further clinical studies demonstrate this technique to be safe and effective, TERIS could potentially constitute a long-term treatment option.
Delaying gastric emptying
As previously discussed, methods of delaying gastric emptying have been a secondary target of a variety of other bariatric endoscopic procedures. Investigation into mechanisms of regulating gastric emptying as a primary treatment has also been underway.
Botulinum toxin A injection
Botulinum toxin A (BTA), commonly known as Botox, is a neurotoxin that inhibits acetylcholine release at the neuromuscular junction. 68 By endoscopically injecting BTA into the gastric wall, the hypothesized result would be a delay in gastric emptying and inhibited ghrelin secretion, both of which function to induce weight loss. Initial human studies conducted in Italy and Mexico demonstrated that the treatment is safe; however, the efficacy was not impressive, with some studies reporting no significant change in body weight, hunger, gastric emptying, or levels of plasma ghrelin or serum leptin. [69] [70] [71] Since then, Foschi et al. studied the mechanism using both antral and fundal injections rather than solely antral injections. This controlled, double-blind study conducted in Italy resulted in significantly more weight loss and satiety and less gastric capacity in the treatment group compared with controls. 72 Furthermore, Li et al., who studied the technique in China, reported significant weight loss accompanied by delayed gastric emptying and a decrease in fasting ghrelin levels. However, results also indicated a decrease in PYY levels, which is undesirable, as PYY is associated with satiety. 73 A recent meta-analysis of this mechanism concluded that intragastric injection of BTA is effective for the treatment of obesity when operationalized in certain ways. Specifically, only wide-area injections including the gastric fundus or body (rather than solely the antrum) are associated with weight loss. Further, multiple (>10) injections are associated with weight loss; however, a large dose (500 IU) is not associated with weight loss. 74 A separate review emphasized that, despite the effects of BTA treatment being short term (3-6 months), because BTA is accessible and not associated with adverse events, it is an attractive option for the treatment of obesity.
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Aspiration therapy
Aspiration therapy (AT) refers to the aspiration of a portion of ingested food contents through an intragastric tube to an out-of-body reservoir.
AspireAssist
In June 2016, the FDA approved AspireAssist (Aspire Bariatrics, King of Prussia, PA) for the treatment of obesity. In the multicenter U.S. pivotal trial, which included 111 patients who underwent treatment with the AspireAssist in addition to lifestyle counseling and 60 patients who underwent lifestyle counseling alone, patients in the treatment group saw significant improvements in indicators of metabolic syndrome and diabetes in addition to significant weight loss. HbA1c levels decreased an average of 0.36% relative to 5.7% at baseline (P < 0.0001). Triglycerides decreased by 9.9% (P = 0.02), and high-density lipoprotein cholesterol increased by 8.1% (P = 0.0001). Furthermore, modest improvement was seen in systolic blood pressure (-1.2%, P = 0.38), diastolic blood pressure (−2.6%, P = 0.06), LDL cholesterol (−4.2%, P = 0.06), and total cholesterol (−2.5%, P = 0.07). However, it is important to note that these improvements were not significantly different from those seen in the lifestyle-counseling group, with the exception of glycated hemoglobin. The mean %EWL at 52 weeks for completers in the AspireAssist group (n = 82) was 37.2 ± 27.5% (14.2 ± 9.8% TBWL) compared with 13.0 ± 17.6% (4.9 ± 7.0% TBWL) in the lifestylecounseling group (n = 31). 76 Small pilot studies have seen more impressive weight loss. At 1 year, Norén and Forssell reported mean %EWL of 54.4 ± 28.8% in a Swedish cohort, while Sullivan et al. reported mean %EWL of 49.0 ± 7.7% in a U.S. cohort. 77, 78 Furthermore, Forssel and Norén, who studied outcomes in a Swedish cohort, reported a mean %EWL at 6 months of 40.8 ± 19.8%. 79 The most common adverse events were peristomal pain, stoma granulation tissue formation, irritation, and infection. 76 A concern with the use of AT is the potential for the promotion of eating disorders. Therefore, it is important to note that there has been no evidence of increased food intake or the induction of adverse eating behaviors in patients using the AspireAssist. 77 This treatment modality consists of the endoscopic insertion of a silicone percutaneous gastrostomy tube, called the A-tube, which is coupled with a SkinPort and an accessory tube for aspiration (Fig. 4) . The endoscopic procedure is completed on an outpatient basis in approximately 15 minutes. There is no clearly defined recovery period, but patients may experience pain following insertion. Two weeks after insertion, the endoscopist cuts the proximal end of the A-Tube to within 1 cm of the abdominal wall and attaches it to the SkinPort. [76] [77] [78] Once the device is installed, patients are instructed to aspire 20 min after each meal, which takes 5-15 min and removes approximately 30% of ingested calories. Use of the AspireAssist must be coupled with regular medical supervision and lifestyle counseling. Interestingly, the device is designed to self-regulate. The connector, which allows for aspiration, contains a counter, which after 115 aspirations will lock the connector, blocking access to the SkinPort. This is a safety measure that protects against long-term use without clinical supervision. 76 AspireAssist is only approved by the FDA for use in patients who are 21 years or older, with a BMI between 35 and 55 kg/m 2 . Patients with a history of disordered eating are not eligible for AT. The device is removable, but has also been approved for long-term use.
There is no indication that AT results in physiological changes that induce weight loss, as with RYGB; however, it has been suggested that the fistula formed between the stomach and abdominal wall owing to the A-Tube may inhibit gastric distention and thus result in earlier satiation. Further discussion of this treatment has highlighted that the behavior changes necessary for proper use of the device align with behavioral suggestions for general weight management, such as increased chewing of food and consumption of water to facilitate aspiration, limiting between-meal snacks to avoid the need for additional aspirations, and developing a meal schedule to accommodate aspiration while on the go.
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Malabsorptive techniques
Malabsorptive endoscopic procedures function through a similar mechanism to RYGB surgery in that they prevent ingested nutrients from having contact with the duodenum and proximal jejunum, which function in nutrient absorption. This mechanism prevents the digestive action of biliary and pancreatic secretions, thus exposing the distal jejunum to undigested nutrients, which further reduces absorption. Moreover, this action may alter incretin pathways, resulting in improved insulin sensitivity in addition to weight loss. 22 Gastrointestinal bypass sleeves EndoBarrier. The duodenojejunal bypass sleeve (DJBS) is the first endoluminal implant to induce weight loss through malabsoprtion. 80 The EndoBarrier (GI Dynamics, Lexington, MA) is a Tefloncovered DJBS that is impermeable to nutrients.
Although it has not yet been approved for use in the United States, a number of clinical trials have been conducted to assess the safety and efficacy of the EndoBarrier device. A recent meta-analysis of the published literature from these clinical trials determined that treatment with the EndoBarrier DJBS had an impact on diabetic control, as evidenced by improvements in HbA1c at 24 weeks (P < 0.001) and after 52 weeks in situ (P < 0.001), which was statistically significant when compared with controls (P = 0.001). 28 Notably, the potential use of the EndoBarrier in reversing type II diabetes mellitus independently of weight loss is under investigation.
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The meta-analysis also found that, on average, patients experienced 35.3% EWL at 12 months (n = 105). Four of the trials compared 12-24 weeks of treatment with the EndoBarrier DJBS (n = 90) with a sham or control arm (n = 84). The mean difference in %EWL compared with a control group was significant at 9.4%. 28 A pivotal multicenter U.S. trial was terminated before completion because the incidence of hepatic abscess formation reached 3.5%. With enrollment of 325/500 patients, analyses revealed that subjects who received the DJBS lost significantly more weight compared with the sham group at 12 months (%TBWL 7.7 ± 9.6% versus 2.1 ± 5.4%, P < 0.0001) and had more significant improvement in HgA1c (-1.1 ± 1.5% versus -0.3 ± 1.6%). Early device retrieval owing to adverse events was necessary in 10.9% of patients. 81 This mechanism works by anchoring the proximal end of the sleeve to the duodenal bulb using a nitinol implant that functions as a self-expanding stent, while the distal end of the sleeve extends into the jejunum. The sleeve extends 65 cm into the small bowel and can remain in situ for 3-12 months. The device functions by preventing contact between ingested food and the lining of the duodenum and proximal jejunum while allowing pancreaticobiliary secretions to travel along the outside of the device to the jejunum, which results in food reaching the mid-jejunum earlier.
The device is placed under general anesthesia using endoscopic and fluoroscopic guidance. A capsule containing the sleeve and anchor is advanced over a guide wire, and the sleeve is deployed in the proximal jejunum. When it is fully extended, the anchoring crown is deployed in the duodenal bulb. Device removal requires the use of a foreign bodyretrieval hood and a procedure-specific grasping device that collapses the anchor.
Gastroduodenojejunal bypass sleeve. Modified DJBSs are currently undergoing clinical trials, including the gastroduodenojejunal bypass sleeve (ValenTx Inc, Carpinteria, CA). This device operates in a similar mechanism as the EndoBarrier, with a major exception: it is longer, at 120 cm, and is secured at the gastroesophageal junction rather than the duodenal bulb, using endoscopic and laproscopic techniques. This modification causes the sleeve to bypass the stomach in addition to the duodenum and proximal jejunum, further mimicking the effects of RYGB and reducing the capacity for intake. 32 In a small clinical trial (n = 12) conducted in Mexico, two patients required early removal of the device owing to intolerance. The remaining 10 patients kept the device in for 12 months. Each of the measured comorbidities, which included diabetes mellitus, hypertension, hyperlipidemia, and the use of antihyperglycemics, improved during the trial. Specifically, there was a mean improvement in fasting glucose of 28% among the entire cohort and a mean improvement of 38% among those with preexisting diabetes mellitus. Furthermore, three of the four patients with preexisting diabetes had over a percentage point drop in their HbA1c values, and the fourth patient also improved to the point of stopping diabetes medication. All patients with hypertension saw improvement, and 71% had blood pressure values in the normal range and were therefore able to stop all antihypertensive medications. The mean change in blood pressure for the entire cohort was -15%. The one patient with hypercholesterolemia experienced complete resolution and stopped medication, and, of the five patients with hypertriglyceridemia, four (80%) had measurements within the normal range and were off all medications at follow-up. The mean decrease in triglyceride levels in the entire cohort was 26%. 82 Upon removal, the device was fully attached and functional in six patients. In these patients, the mean %EWL at 12 months was 54%; however, weight loss was less significant in patients whose device was not fully attached at 12 months. 82 In a 12-week U.S. trial (n = 22), 77% of patients completed the trial period. The four patients who had elevated HbA1c levels preoperatively showed improvement by the end of the trial, and there was a mean of 39.7% EWL. The primary reason for premature removal of the device was early postoperative dysphagia. 83 Notably, these two studies were limited to morbidly obese patients who met the criteria for bariatric surgery. This is a key distinction between the gastroduodenojejunal bypass sleeve and many other endoscopic techniques.
SatiSphere. The SatiSphere device (EndoSphere Inc., Columbus, CA) is another malabsorptive method designed to be endoscopically implanted into the duodenum and gastric antrum to delay the transit time of nutrients. This mechanism is proposed to function by decreasing glucose uptake and thus insulin secretion. Sauer et al. reported success in these outcomes, as well as altered GLP-1 levels and significant weight loss (%EWL of 12.2% at 3 months); however, the study (n = 21), which was conducted in Germany, had to be stopped prematurely owing to migration in 48% of patients. 84 Since then, a second-generation SatiSphere device with antimigration properties was tested in a small study (n = 10) in the Czech Republic. No migrations were reported; however, all devices were prematurely removed within 5 weeks owing to ulcer-like symptoms. Before removal, four patients experienced 5-7% TBWL, thereby demonstrating the efficacy of the technique. Further device modifications are now underway in an effort to enhance patient comfort and reduce the tendency for tissue injury. 85 Other small bowel endoscopic bariatric therapies Revita duodenal mucosal resurfacing. The Revita duodenal mucosal resurfacing procedure (Fractyl Laboratories, Cambridge, MA) was not designed specifically for weight loss but rather to treat one of the most common comorbidities of obesity, type 2 diabetes. By thermally ablating superficial mucosa in the duodenum, the procedure is intended to reset duodenal endocrine cells and thus improve insulin signaling.
Rajagopalan et al. conducted a pilot study (n = 39) in Chile in patients with type 2 diabetes on one or more antidiabetic agents with HbA1c ࣙ7.5% (58 mmol/mol). Twenty-eight patients had a long duodenal segment (LS) ablated (ࣙ9.3 cm, mean 9.3 cm), and 11 patients had a short segment (SS) ablated (<6 cm, mean 3.4 cm). At 3 and 6 months follow-up, HbA1c was improved in all patients. More significant effects were seen in the LS group, which experienced a 2.5% mean reduction in HbA1c at 3 months (1.4% reduction at 6 months) compared with a 1.2% mean reduction in the SS group at 3 months (0.7% reduction at 6 months). Notably, this difference remained significant despite medication reduction in the LS group over the course of the 6-month follow-up.
The procedure was well tolerated, and there were no procedural complications. The most common adverse event was transient abdominal pain. Duodenal stenosis developed in 8% of patients, all of whom were successfully treated with balloon dilation. Notably, root cause analysis of these events resulted in the adaption of procedural changes and device improvements. 86 This procedure involves a specifically designed catheter to deliver hot water into the duodenum for circumferential mucosal lift. This is followed by inflation of a 2.0-cm balloon with heated water for ablation of duodenal mucosa. This two-step procedure is repeated successively until the desired length of mucosal ablation is achieved.
The results reported here are promising, and further testing will likely occur in the coming year, which may shed light on longer-term outcomes.
Incision-less anastomosis system. The incisionless anastomosis system (IAS, GI Windows, Boston, MA) is a system of self-assembling magnets that functions to create a dual-path enteral bypass, thereby allowing a portion of ingested nutrients to bypass the small bowel.
The IAS system was recently tested in a first human trial (n = 10) in the Czech Republic. The dual-path bypass was successfully and safely created in 100% of patients, and, at 6 months follow-up, significant improvements in HbA1c and fasting blood glucose levels were noted. All of the patients who were originally prediabetic normalized (n = 3), and all diabetic patients (type 2 only) either reduced or ceased medication (n = 4). The mean %EWL was 28.3% (10.6% TBWL). No serious adverse events occurred, and the most common adverse events-nausea and diarrhea-resolved acutely in most patients and with diet and standard treatment in a minority of patients. The IAS is deployed endoscopically under general anesthesia (with both endoscopic and fluoroscopic visualization) to form magnetic octagons in both the jejunum and ileum that mate. An anastomosis forms through necrosis in the tissues undergoing magnetic compression.
The results are very encouraging, and further clinical study will likely occur in the near future. 87 
Conclusions
Advancements in the field of bariatric endoscopy have occurred in the past year and will likely continue to make up a growing sector of obesity treatment in the coming decade (Table 1) . This field bridges an important gap between lifestyle counseling and pharmaceutical treatment of obesity and surgical intervention and is unique in the ability to be repeated throughout life for continued management of this chronic disease. The true strength of these bariatric interventions lies not only in weight loss but also in the reduction of comorbidities associated with obesity.
